Last update 01 Nov 2024

TYK2 x JAK3 x ARK5

Basic Info

Related Targets
TYK2JAK3ARK5

Related

1
Drugs associated with TYK2 x JAK3 x ARK5
OST-122
Target
ARK5 x JAK3 x TYK2
Mechanism
ARK5 inhibitors [+2]
Active Org.
Oncostellae SLOncostellae SL
Originator Org.
Oncostellae SLOncostellae SL
Active Indication
Colitis, Ulcerative
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with TYK2 x JAK3 x ARK5
NCT04353791 / CompletedPhase 1/2
A Phase Ib/IIa, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral Treatment With OST-122 in Patients With Moderate to Severe Ulcerative Colitis
EUCTR2019-004090-50-ES / Unknown statusPhase 1/2
A Phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis
100 Clinical Results associated with TYK2 x JAK3 x ARK5
Login to view more data
100 Translational Medicine associated with TYK2 x JAK3 x ARK5
Login to view more data
0 Patents (Medical) associated with TYK2 x JAK3 x ARK5
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free